The European Glaucoma Prevention Study and the Ocular Hypertension Treatment Study: Why do two studies have different results?

Current Opinion in Ophthalmology

Volumn 17, Issue 2, 2006, Pages 138-141

  Parrish II, Richard K ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Dorzolamide; Ocular hypertension; Primary open angle glaucoma

Indexed keywords

DORZOLAMIDE;

CLINICAL EXAMINATION; CLINICAL TRIAL; DISEASE COURSE; EUROPE; GLAUCOMA; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; METHODOLOGY; PRIORITY JOURNAL; REVIEW;

EID: 33646897877     PISSN: 10408738     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (9)

1. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study. A randomized trial determines that topical ocular hypertensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002; 120:701-713.
2. European Glaucoma Prevention Study (EGPS) Group. Results of the European Glaucoma Prevention Study. Ophthalmology 2005; 112:366-375. Methodologic issues cast doubt on the conclusion that IOP-lowering treatment does not reduce the rate of progression from ocular hypertension to POAG.
3. Higginbotham EJ, Gordon MO, Beiser JA, et al. The Ocular Hypertension Treatment Study: topical medication delays or prevents primary open-angle glaucoma in African American individuals. Arch Ophthalmol 2004; 122:813-820. This landmark publication convincingly demonstrates a comparable benefit of IOP-lowering in patients of African-American ancestry.
4. Heijl A, Leske MC, Bengtsson B, et al. Early Manifest Glaucoma Trial Group. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 2002; 120:1268-1278.
5. Collaborative Normal-Tension Glaucoma Study Group. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressure. Am J Ophthalmol 1998; 126:487-497.
6. Quigley HA. European Glaucoma Prevention Study, letter to the editor. Ophthalmology 2005; 112:1642-1643. The correspondent clearly describes three likely explanations why the EGPS failed to determine a treatment benefit with topical dorzolamide therapy compared with placebo treatment.
7. Miglior S, Pfeiffer N, Zeyen T, et al. Writing Committee of the EGPS Group. Author reply. Ophthalmology 2005; 112:1643-1645.
8. European Glaucoma Prevention Study (EGPS) Group. The European Glaucoma Prevention Study design and baseline description of the participants. Ophthalmology 2002; 109:1612-1621.
9. Gordon MO, Kass MA, Ocular Hypertension Treatment Study Group. The Ocular Hypertension Treatment Study design and baseline description of the participants. Arch Ophthalmol 1999; 117:573-583.